Drug profile · INN
romosozumab
EVENITY
romosozumab (EVENITY) is a sclerostin inhibitor. Associated with Amgen.
EMA: approved TGA: approved PMDA: approved Musculo-skeletal system (M05) M05BX
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — romosozumab
- Class
- Musculo-skeletal system (M05)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
romosozumab (EVENITY) is a sclerostin inhibitor. Associated with Amgen.
Key facts
INN romosozumab
Brand EVENITY
Mechanism Sclerostin inhibitor
Target Sclerostin
Therapeutic class Musculo-skeletal system (M05)
ATC code M05BX
Originator Amgen
Mechanism of action
Sclerostin inhibitor
Primary target: Sclerostin
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is romosozumab?
romosozumab (EVENITY) is a sclerostin inhibitor. Associated with Amgen.
What is the brand name for romosozumab?
EVENITY is a marketed brand name for romosozumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.